[
    [
        {
            "time": "",
            "original_text": "“植发第一股”雍禾医疗港股IPO认购 年末港股打新掀高潮",
            "features": {
                "keywords": [
                    "雍禾医疗",
                    "港股IPO",
                    "年末",
                    "打新",
                    "高潮"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "“植发第一股”雍禾医疗港股IPO认购 年末港股打新掀高潮",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "前后脚披露罕见大单，博腾、凯莱英接到70亿合同，疑似为新冠口服药",
            "features": {
                "keywords": [
                    "博腾",
                    "凯莱英",
                    "大单",
                    "新冠口服药",
                    "合同"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "前后脚披露罕见大单，博腾、凯莱英接到70亿合同，疑似为新冠口服药",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 10,
                "Impact": 10,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 8,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        },
        {
            "time": "",
            "original_text": "跨年行情如何布局？机构普遍看好这三大赛道",
            "features": {
                "keywords": [
                    "跨年行情",
                    "布局",
                    "机构",
                    "赛道"
                ],
                "sentiment_score": 0.65,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "跨年行情如何布局？机构普遍看好这三大赛道",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "【国金医药】凯莱英点评：港股发行区间公布，未来增长再提速",
            "features": {
                "keywords": [
                    "国金医药",
                    "凯莱英",
                    "港股发行",
                    "增长提速"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【国金医药】凯莱英点评：港股发行区间公布，未来增长再提速",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "国金证券维持凯莱英买入评级：港股发行区间公布，建议重点关注",
            "features": {
                "keywords": [
                    "国金证券",
                    "凯莱英",
                    "买入评级",
                    "港股发行",
                    "重点"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "国金证券维持凯莱英买入评级：港股发行区间公布，建议重点关注",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "全球小分子CDMO领跑者，凯莱英(6821.HK/002821.SZ)赴港上市",
            "features": {
                "keywords": [
                    "凯莱英",
                    "CDMO",
                    "赴港上市",
                    "全球领跑者"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "全球小分子CDMO领跑者，凯莱英(6821.HK/002821.SZ)赴港上市",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "东吴证券月度策略及金股组合——从震荡走向春季躁动",
            "features": {
                "keywords": [
                    "东吴证券",
                    "月度策略",
                    "金股组合",
                    "春季躁动",
                    "震荡"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "东吴证券月度策略及金股组合——从震荡走向春季躁动",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 6,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "九洲药业逾2亿元收购亏损药厂 转型CDMO需跟踪产能空间 亏损",
            "features": {
                "keywords": [
                    "九洲药业",
                    "收购",
                    "亏损药厂",
                    "转型CDMO",
                    "产能空间"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "九洲药业逾2亿元收购亏损药厂 转型CDMO需跟踪产能空间 亏损",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]